WHY THE NEXT DECADE OF MEDTECH BELONGS TO INFRASTRUCTURE

For years, the MedTech industry has been defined by a cycle of incremental clinical improvement.

Success was measured by the “better mousetrap” – a slightly sharper scalpel, more flexible stent, or marginally more accurate sensor.

As we move into 2026, it is becoming clear that this era of standalone product excellence is no longer the primary driver of market value.

This fundamental shift isn’t accidental; it’s being driven by a powerful convergence of forces. On the one hand, relentless economic pressure and the transition to value-based care are forcing healthcare operators to seek not just incremental clinical gains, but also radical operational efficiency. They are now looking to MedTech as a core strategy to address their largest and most strained resource: their workforce.

On the other hand, this is only possible because technology has reached a tipping point. The convergence of cloud computing, artificial intelligence (AI), and a growing mandate for interoperability means we can finally move beyond isolated devices. We can now build connected systems that don’t just generate data, but also analyse, interpret, and seamlessly integrate it into the clinical workflow.

RISE OF THE PROCEDURAL PLATFORM

The most immediate manifestation of this shift is the rise of the procedural platform.

For most hospitals today, operational complexity is staggering. During a single complex procedure – whether in orthopaedics or interventional cardiology – a hospital’s procurement and clinical teams are often forced to manage an incredibly fragmented supply chain.

They may juggle relationships with up to 15 different vendors for a single operating room, resulting in 15 different contracts, 15 sets of inventories, and 15 potential points of failure on any given day. It is profoundly inefficient and, frankly, unsustainable.

Hospitals are now demanding simplicity over variety. The key question for new equipment is no longer just “What does this product do?”, but “How does this product fit into our existing system?”.

The market is moving towards a model where hospitals buy outcomes and efficiency rather than individual tools. This transition from fragmentation to integrated platforms is where the significant financial prize now lies.

Our analysis shows that MedTech companies with a clear platform strategy are not only growing faster, but also commanding exit multiples that are, on average, two to three turns higher than standalone product companies in the same vertical.

FROM HARDWARE SALES TO DATA INFRASTRUCTURE

Perhaps the most profound change is the shift in the value of these workflows.

We are seeing a transformation of devices from simple hardware to data infrastructure. The buyer’s priorities are shifting accordingly; for many new device categories, seamless integration into the electronic medical record now outranks incremental clinical features as the top purchasing criterion.

This is act one of a larger story, where the data becomes more valuable than the device itself. MedTech firms are responding by transforming from industrial manufacturers into technology companies, aggressively retooling their talent base to hire for software and data science roles whilst hardware hiring remains flat.

The financial markets are rewarding this pivot with enormous premiums, valuing a recurring dollar of data revenue significantly higher than a one-time dollar of hardware revenue.

The goal is no longer just to build a device, but to build an ecosystem where the data infrastructure makes the system indispensable to both patients and clinicians.

AUTOMATION AS A STRUCTURAL SOLUTION

Whilst data solves digital complexity, automation is addressing the crises of the physical world.

A hidden cost in healthcare is the burden on labs and factory-floor workforces. Recent analysis suggests that, in many quality control labs, more than 60 percent of a skilled technician’s time is spent on manual sample handling, tracking, and documentation rather than value-added analysis. This is the primary source of human error and costly compliance deviations.

In this context, automation is no longer an optional upgrade; it is a structural necessity. By deploying modular robotics and automated genomic sequencing workflows, companies are delivering step-change improvements in productivity and speed.

These systems are increasingly underwritten as long-lifecycle infrastructure with high switching costs and deeply embedded, recurring revenue. They are not merely machines; they are the compliant, high-uptime manufacturing infrastructure that the entire life sciences sector relies on to function.

REANCHORING CARE BEYOND THE HOSPITAL

Finally, we are seeing a reanchoring of the healthcare system away from the hospital as the default centre of gravity.

Driven by constrained capacity and the maturation of remote monitoring and AI-enabled triage, high-acuity care is migrating down the acuity curve.

This shift is durable because outcomes and economics are finally aligned; hospital-at-home models are associated with lower readmissions and improved patient satisfaction.

For MedTech, the implication is that value increasingly accrues to companies that enable care beyond the four walls of the acute setting.

This is not about replacing hospitals, but expanding the infrastructure of care through monitoring networks, connected devices, and analytics layers.

The highest value is being created not by the device that goes into the home, but by the physical, financial, and digital plumbing that makes decentralised care operationally viable in the first place.

As we look to the next decade, the single thread that ties these strategies together is that the landscape no longer rewards companies that simply sell better products – it rewards those who build indispensable infrastructure.

These assets become embedded in daily operations, create deep competitive moats, and ultimately command the strategic valuations that define market leadership.

The infrastructure mindset is no longer just a strategic advantage; it is the primary driver of value creation in our industry.

The post Houlihan Lokey : Why the Next Decade of MedTech Belongs to Infrastructure appeared first on Healthcare Outlook.

ENDING MALARIA, REWRITING THE FUTURE

Founded in 1999, Medicines for Malaria Venture (MMV) is a leading not-for-profit product development partnership (PDP) dedicated to the discovery, development, and delivery of affordable, innovative antimalarial drugs, particularly for vulnerable populations. 

Following recent economic analysis published in a Lancet Global Health study – which revealed 13-fold return in monetised health benefits for every USD$1 invested in MMV – the case for sustained investment in malaria drug development is garnering increased attention. 

“Findings of this kind change the tone of the funding conversation,” opens Dr Martin Fitchet, CEO of MMV.  

Whilst donors have historically faced competing priorities as drug development can appear a high-risk investment with long timeframes, the economic analysis published in the report allows drug development to be more widely discussed in terms of return on investment (ROI). 

“This is ultimately how a lot of funding decisions are made,” Fitchet adds.  

These figures, analysing MMV’s impact between 2000 and 2023, tangibly reflect that investing in drug development through the PDP model – which MMV believes to be the most efficient way to bridge the gap in new drugs for malaria – delivers exceptional value, resulting in fewer deaths across high-burden malaria-endemic countries. 

“For decision-makers facing difficult budget choices, this kind of independent study matters as it demonstrates credible evidence that provides a basis for multi-year funding commitments that promise sustained and measurable results,” insights Fitchet.  

As drug development requires long timelines and steady backing, evidence like this helps make the case for sustained funding so the discovery, development, and delivery of the next generation of antimalarials continues.  

TRUST THE PROCESS 

With the study accounting for both successful and failed R&D projects undertaken by MMV, Fitchet notes the importance of acknowledging the risks inherent to drug development when advocating for sustained investment.  

“It is fundamental to acknowledge these risks as drug development is inherently uncertain. Any robust assessment must account for the fact not every candidate succeeds,” he says.  

At the same time, Fitchet points out how failed R&D projects can also be a sign of success.  

“If we didn’t have failures, it would mean we were not being ambitious enough.”  

As such, analysis that truly acknowledges risk by including the costs of both successful and failed projects is integral.  

“We also applied conservative assumptions when estimating realised returns and only calculated the number of deaths averted between 2000 and 2023, not considering future deaths that will be averted from MMV-supported products,” Fitchet reflects. 

MMV manages a portfolio of drugs, as opposed to a single drug candidate, which means over the period assessed, it was overseeing the clinical development of more than 45 products – of which just 16 reached the market.  

As such, by spreading risk across a diversified pipeline and working in partnership with both public and private actors, MMV is reducing the impact of individual failures. 

“Being open and transparent about risk strengthens rather than weakens the case for sustained investment as it corroborates trust in the development process,” he confirms.  

BROADENING HORIZONS

According to the World Health Organization (WHO) World Malaria Report, malaria cases reached 282 million annual cases in 2024, whilst drug resistance continues to advance in Africa.  

As such, MMV is adapting its R&D pipeline to stay ahead of emerging resistance and safeguard the efficacy of current treatments.  

“Our focus is on closing the most urgent gaps in treatment. Existing medicines remain effective in many settings, but antimalarial drug resistance is advancing and poses a clear threat to global elimination efforts,” Fitchet warns.  

Without sustained investment, MMV faces the risk of losing hard-earned gains – which would, in turn, mean losing many more lives each year.  

Together with its partners, the organisation is actively broadening the range of available treatments so programmes are not reliant on a narrow set of options.  

MMV has already seen progress in this regard, with Coartem® Baby – the first antimalarial approved to treat newborns and young infants – and ganaplacide-lumefantrine – the first novel-acting non-artemisinin therapy in 25 years which recently completed late-stage clinical trials – both developed with Novartis.  

“These are important steps, but our pipeline must continue to innovate as malaria and its risks also adapt,” he outlines. 

From discovery through to delivery, the organisation works end-to-end in collaboration with partners across sectors and regions.  

“Our aim is to align R&D with evolving epidemiology and country needs. By advancing new compounds and optimised combinations, and by prioritising affordability and access, we seek to protect the effectiveness of current treatments whilst preparing credible alternatives for the future,” Fitchet details.

DISCOVERY, DEVELOPMENT, DELIVERY 

In recent years, the strength of PDP models has become clear, particularly when it comes to lowering risk and accelerating innovation – MMV’s own PDP differentiates the organisation from traditional pharmaceutical R&D models.  

“Along with other PDPs, we were formed off the back of market failure in delivering necessary lifesaving medicines,” Fitchet informs.  

Driven by public health needs as opposed to commercial return, MMV pools both donor funding and industry expertise to coordinate the discovery, development, and delivery of its medicines for a disease that disproportionately affects the poorest communities.  

“Our model lowers risk by sharing costs and capabilities and managing a balanced portfolio,” he adds. 

Since its inception, MMV – with its pharmaceutical and research partners – has brought forward 19 medicines that were distributed to around 1.48 billion people.  

Independent ROI analysis suggests this type of partnership model can deliver strong health and economic value whilst remaining accountable to its funders and the communities it serves.  

AHEAD OF THE CURVE 

Looking ahead, there are many challenges MMV faces when it comes to sustaining its momentum in the fight against malaria. 

“Funding is constrained, cases remain high, and resistance is fast-evolving,” Fitchet exemplifies. 

Further to this, drug development cycles are typically long and interruptions to support can delay promising candidates from getting to market.  

“This is why positive findings like the ones published are so important – they show material benefits for sustained investment in critical R&D for malaria elimination,” he shares. 

Elsewhere, MMV continues to innovate to stay ahead of emerging threats. 

“No single organisation can do this alone. We see MMV’s role as convening private and public actors to ensure innovation is aligned around shared public health goals and treatment reaches those most at risk,” Fitchet assesses. 

This includes working with both academia and industry to recognise their need to protect intellectual property, whilst negotiating terms that allow new medicines to be supplied through public sector channels at affordable prices – typically on a no-profit, no-loss basis. 

“Sustained commitment from governments, industry, and funding partners is therefore vital to continue to build on the important groundwork,” he passionately concludes.

The post Medicines for Malaria Venture : Ending Malaria, Rewriting the Future appeared first on Healthcare Outlook.

AN ECOSYSTEM OF INNOVATION

With the release of HSBC Innovation Banking Life Sciences’ UK & Europe: Life Sciences & Healthcare Venture Financing Report, which presents key findings from the 2025 financial year, a renewed sense of momentum can be felt across life sciences in the UK and Europe, bolstered by increasing deal activity and larger funding rounds.

For Dominick Kennerson, Director, Business Development, Life Sciences and Healthcare, these signals indicate not just recovery, but a more resilient and sustainable funding environment.

“There are a few things that point to a very healthy market – first is the sheer size and scale of funding,” Kennerson opens.

In 2025, a number of mega-rounds took place, with significant activity across the BioTech, BioPharma, and TechBio fields.

Notably, many of these rounds are occurring at the pre-clinical and Phase 1 stages, reinforcing investor confidence in early-stage innovation.

This pipeline of funding activity is complemented by strong investor appetites around emerging technologies, particularly artificial intelligence (AI).

“We are also witnessing strong investor appetite for TechBio platforms – particularly those built around AI-driven models.

“Investors don’t want to miss the opportunities presented by these technologies,” he outlines.

CRITICAL RELATIONSHIP-BUILDING

Beyond capital availability, Kennerson highlights relationship-building as one of the most underutilised opportunities for scaling companies within the HealthTech sector.

As companies progress into later funding stages – particularly Series B and C – the need for international investor syndicates and collaboration becomes more pronounced.

“A best practice for companies looking to raise larger scale-up rounds is to start building those relationships well before they need capital,” Kennerson explains.

This is a dynamic that’s reinforced by how deals are sourced within the sector.

“I spoke recently with a US investor who said 95 percent of their inbound deal flow is referral-led, meaning one investor introducing another,” he reveals.

As such, relationship-building at this level is not just beneficial – it’s critical to unlocking capital.

MAJOR GROWTH DRIVER

As it continues to emerge as a major growth driver within the UK healthcare market, HealthTech tends to fall into two categories.

These are businesses focused on improving NHS efficiency statistics, as well as those aimed at treating patients’ needs as early as possible through preventative and consumer-led care – a dual approach reflected in recent high-profile funding rounds.

“Some of the largest HealthTech rounds in 2025 came from companies such as Neko Health, which is building an expanded clinic model and now operates more than a half-dozen clinics across the UK, having raised around £210 million to build out this infrastructure,” Kennerson highlights.

Another major funding round came from Cera Care (Cera), which is focused on home health services, demonstrating the importance of treating people at home where possible to reduce pressures on the NHS, whilst supporting the UK’s demographic trend to ageing.

Elsewhere, Kennerson has noticed an important shift taking place at the early stage.

“We are seeing companies operating something close to a bootstrap-blitzscale model,” he insights.

Indeed, rather than raising capital early on, many have found themselves building revenue and strengthening fundamentals before seeking institutional investment – a shift reflected at early-stage funding.

“The average first financing in HealthTech in FY25 was £5.8 million. The year before that it was around £3.7 million, and in 2023 it was around £3.3 million,” Kennerson points out.

As a result, companies are entering Series A rounds with stronger fundamental financial metrics and larger sums, contributing to the emergence of what Kennerson calls the “new Series A company”.

This evolution has also given rise to the possibility of a ‘one-and-done’ funding round where a single, well-capitalised raise may be efficient to scale to profitability and potential exit.

COLLABORATION AT SCALE

For Paula Burke, Director, HealthTech and Medical Devices at HSBC Innovation Banking Life Sciences, collaboration is defining the next phase of healthcare innovation – particularly where AI, data, and biology intersect.

“The partnerships I’m most excited to see are those bringing together data, AI, and biology with clinical workflow at scale,” she tells us.

These collaborations are becoming increasingly sophisticated, with recent examples including Tempus, AstraZeneca, and Pathos AI’s multi-year, strategic partnership to accelerate cancer drug discovery and precision medicine, and Isomorphic Labs’ partnerships with both Eli Lilly and Novartis to revolutionise drug discovery using AI.

“What’s interesting is these kinds of partnerships are no longer centred around a single asset but increasingly focused on AI platforms and data systems that can be applied across multiple programmes,” Burke adds.

AI is becoming increasingly embedded in everyday healthcare operations. For example, Burke cites Novo Nordisk’s collaboration with OpenAI to integrate advanced intelligence across the entire pharmaceutical value chain.

Developments such as these point to a broader shift in how innovation is being delivered.

FROM POTENTIAL TO IMPACT

With AI-enabled drug discovery and precision medicine already translating into real-world impact – albeit at different stages of maturity.

This is particularly evident in oncology, where genomic profiling and liquid biopsies are helping guide diagnoses and treatments.

Advances are also being seen in reducing treatment-related risks, with genetic testing to reduce avoidable side effects – including from typically invasive treatments such as chemotherapy.

AI-driven drug discovery, meanwhile, is gaining traction. Whilst still in its early stages, AI’s impact on trial speed, selection, and execution is already being keenly felt, with stronger clinical evidence expected in the near future.

“If precision medicine helps us choose the right treatment, AI can create more precise treatments in the first place,” Burke insights.

Indeed, AI can support target selection, the design of biomarker-led or mutation-specific therapies, and the identification of patient subgroups more likely to respond to treatment.

INNOVATING INTELLIGENT SOLUTIONS

Alongside HealthTech, MedTech is also undergoing rapid recent change, driven by advances in AI, connectivity, and data integration.

“MedTech devices are becoming more intelligent and connected to continuous patient data whilst being less invasive,” Burke outlines.

In neurology, for example, innovation is already improving outcomes, with AI-enabled stroke imaging tools improving early diagnosis and treatment decisions, helping clinicians detect issues earlier and intervene faster.

At the same time, continuous monitoring is reshaping care delivery, with long-term monitoring moving beyond the hospital.

“This helps support earlier intervention, better chronic disease management, and more care delivered at home,” she emphasises.

This shift is also evident in the convergence of consumer and clinical health technologies.

“Wearable fitness technology companies such as Oura and Whoop have evolved beyond fitness tracking into broader health platforms capable of generating continuous health data,” informs Burke.

Another area of rapid advancement is surgical robotics, with a new generation of robotics companies entering the market, making surgery more precise, less invasive, and more accessible.

STRUCTURAL STRENGTHS

Looking ahead, both Kennerson and Burke emphasise the structural strengths of the UK and Europe, particularly their academic ecosystems and talent base.

“The major advantage for the UK and Europe is the university system. The UK’s ‘Golden Triangle’ – including Oxford, Cambridge, and the London universities – offer an exceptional pipeline of talent.

“This is why innovative drug discovery companies such as Google DeepMind and Isomorphic Labs were created here in the UK – both of which are the brainchild of Sir Demis Hassabis, who graduated from University College London in 2019,” Kennerson details.

With funding options improving for start-ups and scale-ups – particularly in the £20 million to £50 million range – Q1 2026 has also seen healthier BioTech and BioPharma fundraising.

Burke notes how alternative financing structures are increasingly prominent, with more companies leveraging alternative financing alongside equity rounds to extend runway, support hiring, and accelerate commercial build-out.

As HSBC Innovation Banking is Europe’s most active debt provider in this space, supporting companies as they scale and helping regional players to thrive is deeply important.

REASON FOR OPTIMISM

Despite ongoing challenges, both Kennerson and Burke remain optimistic about the future of the sector.

For Kennerson, the emergence of a new generation of companies adopting more sophisticated funding strategies is part of a broader shift towards capital efficiency and optionality.

“The companies that are increasingly asking about non-dilutive financing and bank financing are thinking differently about growth and looking for smarter ways to fund it,” he observes.

Burke’s optimism, meanwhile, lies in the transformative potential of AI in what is one of the largest data generating industries in the world.

“The healthcare industry produces enormous volumes of data through electronic health records, wearable sensors, sequencing, and clinical trials.

“Historically underutilised, this data is now becoming actionable, with AI changing our ability to turn data into scalable insight,” she states.

From personalised medicine to preventative care and faster drug development, the implications are far-reaching.

“At scale, AI has the potential to democratise healthcare by extending better care outcomes to communities that have historically been underserved,” Burke confidently concludes.

The post HSBC Innovation Banking Life Sciences’ UK & Europe appeared first on Healthcare Outlook.

Issue 14

Hospital & Medical Center

Horizon Health Network : Pathways to Patient-Centered Progress

Horizon Health Network stands out as a leader in Canadian healthcare. President and CEO Margaret Melanson shares the organization’s innovative approaches and dedication to quality across its wide network of hospitals and facilities in New Brunswick.

By

Callum Ovenstone

Rachel Carr

May 19, 2026

Read More

Healthcare Providers

Newport Healthcare : Mental Health Matters

For Newport Healthcare, supporting patients at every stage of their mental health journey is a year-round responsibility. The executive team discusses providing compassionate, individualized care that empowers young people to heal and grow.

By

Callum Ovenstone

Jack Salter

May 19, 2026

Read More

Hospital & Medical Center

Joseph Brant Hospital : Project Harmony

A new integrated health information system will enable more seamless care for patients and improved experiences for healthcare providers at Joseph Brant Hospital, whose CEO, Eric Vandewall, reveals more about the implementation of Epic.

By

Callum Ovenstone

Jack Salter

May 19, 2026

Read More

Eye Care

John A. Moran Eye Center : Committed to Hope, Understanding, and Treatment

The John A. Moran Eye Center at the University of Utah is recognized for delivering compassionate, comprehensive, and high-quality care. Jeff Pettey, MD, MBA, CEO and Chair of the Department of Ophthalmology and Visual Sciences at the University of Utah, shares how the center is shaping the future of eye care.

By

Callum Ovenstone

Lauren Kania

May 19, 2026

Read More

Emergency Medical Response

London Fire Brigade : Meeting Tomorrow’s Fire Service Needs Today

Now more than ever, London Fire Brigade must go above and beyond to protect the UK capital, which is witnessing fire risk levels like never before. Jonathan Smith, Commissioner, updates us on the Brigade’s plan of action to uphold the city’s safety.

By

Cameron Lawrence

Lucy Pilgrim

May 20, 2026

Read More

Diagnostics

Hardy Diagnostics : Defining the Future, Transcending the Ordinary

Hardy Diagnostics is the third-largest microbiological culture media manufacturer in the US, with a reputation for supplying quality products at a fair price with great customer service. We learn more from CEO, Chris Catani.

By

Callum Ovenstone

Ed Budds

May 19, 2026

Read More

Therapy

Elemind : Sleep On Demand

Elemind is pioneering read-write neurotechnology – the first wearable that can actively improve health in real time, not just measure it. Meredith Perry, co-Founder and CEO, tells us more about redefining what’s possible in neurotechnology and sleep science.

By

Lauren Kania

May 19, 2026

Read More

Expert Eye

Houlihan Lokey : Why the Next Decade of MedTech Belongs to Infrastructure

Paul Tomasic, Managing Director and Head of European Healthcare at Houlihan Lokey, outlines why the sector’s financial prize has shifted from hardware to the underlying digital and physical plumbing of healthcare.

By

Paul Tomasic

May 20, 2026

Read More

Healthcare Insights

HSBC Innovation Banking Life Sciences’ UK & Europe

Following the release of HSBC Innovation Banking Life Sciences’ UK & Europe: Life Sciences & Healthcare Venture Financing Report for FY25, we sit down with Paula Burke, Director, HealthTech and Medical Devices, and Dominick Kennerson, Director, Business Development, Life Sciences and Healthcare.

By

Lily Sawyer

May 20, 2026

Read More

Pharmaceutical

Medicines for Malaria Venture : Ending Malaria, Rewriting the Future

Medicines for Malaria Venture is continuing to innovate its R&D pipeline, collaborate with stakeholders, and refine its product development partnership model. Dr Martin Fitchet, CEO, tells us more.

By

Lily Sawyer

May 20, 2026

Read More

Healthcare Insights

Youvit : Making Health Delightful

Youvit has pioneered a lifestyle supplement brand built around delightful, one-a-day gummy vitamins tailored to meet the needs of millennial and Gen-Z customers across Southeast Asia. Wouter van der Kolk, co-Founder and CEO, shares more.

By

Lily Sawyer

May 20, 2026

Read More

Healthcare Supply Chain

Zipline Rwanda : Autonomous Delivery Across Rwanda

Rwanda is to become the first country in the world with nationwide autonomous delivery, including Africa’s first urban drone delivery network. We learn about this historic expansion agreement with Pierre Kayitana, Country Director of Zipline Rwanda.

By

Jack Salter

May 20, 2026

Read More

The post Healthcare Outlook Issue 14 appeared first on Healthcare Outlook.

AUTONOMOUS DELIVERY ACROSS RWANDA

A decade ago, Rwanda became the first country in the world to launch Zipline’s national autonomous medical delivery service.

Zipline, an artificial intelligence (AI) and robotics company, designs and operates autonomous logistics systems that enable on-demand delivery of blood, vaccines, and essential medicines, fully integrated into national health systems.

In Rwanda, the network supports nationwide coverage and has contributed to improvements in access to healthcare, including a reported 51 percent reduction in maternal deaths.

Now, under a historic expansion agreement between the government and Zipline, Rwanda will also become the first country with full nationwide autonomous logistics coverage.

It will deploy Zipline’s urban delivery system, known as Platform 2 (P2), starting in the capital, Kigali, where a large share of the country’s healthcare demand is concentrated.

“In addition, Rwanda will host Africa’s first AI and robotics testing and research centre, strengthening its position as a leader in advanced technology and innovation on the continent,” acclaims Pierre Kayitana, Country Director of Zipline Rwanda.

“The expansion also includes the construction of a third long-range distribution hub in Karongi, complementing existing hubs in Muhanga and Kayonza.”

The network will support approximately 350 local jobs and further integrate delivery data into Rwanda’s national health information and emergency response systems.

Importantly, the model reflects a strong government-led approach. The US government is providing upfront infrastructure funding, whilst the Rwanda government is committed to financing ongoing operations.

“This ensures the system is financially sustainable, nationally operated, and embedded within Rwanda’s broader strategy for resilient, technology-driven healthcare,” Kayitana affirms.

ADVANCED LOGISTICS LEADER

By scaling what began as an innovative pilot into permanent national infrastructure, Rwanda has cemented its position as a global leader in advanced logistics.

What started as a targeted effort to improve access to blood in a handful of hospitals has evolved into a nationwide autonomous delivery network embedded in the public health system.

“Today, Zipline is responsible for delivering approximately 75 percent of Rwanda’s national blood supply outside of Kigali,” highlights Kayitana.

This next phase goes further; by hosting Zipline’s first overseas R&D hub, Rwanda is positioning itself not only as a user of frontier technology, but as a place where the next generation of AI, robotics, and autonomous logistics systems will be developed. In doing so, the country is helping shape the future of global supply chains.

A decade of operational data shows the tangible impact of this approach, as Zipline’s system has reduced medical waste by enabling centralised inventory and on-demand delivery.

It has also dramatically improved emergency response times for time-critical treatments such as blood for maternal haemorrhages.

This demonstrates that high-tech logistics can be both effective and economically efficient when deployed at national scale.

“Independent studies consistently find that Zipline’s network ranks amongst the highest-impact and most cost-effective health system interventions studied in recent years – improving outcomes across immunisation, maternal health, nutrition programmes, and emergency care whilst strengthening the reliability of national supply chains,” Kayitana highlights.

AUTONOMOUS DELIVERY SYSTEM

Zipline’s next-generation autonomous delivery system, P2, is designed for fast, quiet, and highly precise deliveries in dense urban environments.

Unlike earlier systems built primarily for long-range medical deliveries, P2 is designed to operate within cities, enabling items to be delivered directly to homes, hospitals, offices, and public spaces with very high accuracy.

“The system uses a new aircraft design with a smaller delivery droid that lowers packages gently to the ground, allowing for maximum accuracy, which makes it well-suited for urban settings like Kigali,” explains Kayitana.

This progress has been championed by Rwandan authorities, notably the Minister of Health, Dr Sabin Nsanzimana, who was recently named to the TIME100 Next list for his work in strengthening Rwanda’s health system through data-driven decision-making and innovation.

Under his leadership, Rwanda has benefitted from the impact of the integration of technology into healthcare delivery, allowing for improved and more reliable access to essential services.

The introduction of the urban delivery system in Kigali will address the high concentration of healthcare demand in the capital, enabling fast and precise deliveries within dense city environments.

“Introducing P2 in Rwanda means the country will be the first in Africa to deploy this type of urban autonomous logistics system,” Kayitana tells us.

“It will expand the range of deliveries that can be supported, improve response times in cities, and further integrate autonomous delivery into everyday healthcare and commercial logistics.”

LONG-RANGE COVERAGE

The new long-range distribution centre in Karongi is built on the border between Rwanda and the Democratic Republic of the Congo (DRC), intended as a symbol of peace between the two countries.

Its overall goal is to expand delivery capacity, expected to serve approximately 200 health posts and 60 major health facilities, reaching more than 2.9 million people.

“Together with the other hubs, it will help deliver full nationwide coverage, allowing Zipline’s network to support more than 11 million people across Rwanda,” informs Kayitana.

The addition of a third hub guarantees the provision of long-range coverage across the country, ensuring even remote and hard-to-reach communities can receive critical medical supplies quickly.

By integrating this connected network into national health systems, Rwanda is building a logistics infrastructure that ensures essential medicines and supplies can reach communities quickly and reliably, regardless of location.

The new AI and robotics testing facility, meanwhile, will serve as Zipline’s first R&D hub outside the US.

“This facility will allow us to test our technology in a range of real-world conditions, including different climates and terrain, helping improve the reliability and performance of aircrafts and systems globally,” Kayitana insights.

“It will also support the development of local talent by creating opportunities to work directly on advanced robotics and AI systems.”

INFLUENCE BEYOND LOGISTICS

Rwanda is demonstrating that autonomous delivery works at national scale, and in real-world conditions, as part of a government-led system.

“Independent research has increasingly validated the transformative power of this system, demonstrating that its influence extends far beyond mere logistics,” notes Kayitana.

“By optimising the delivery of critical goods, it has fundamentally reshaped supply chain efficiency – drastically reducing waste and theft whilst virtually eliminating the risk of stockouts.”

The impact on public health is even more profound, representing some of the most significant outcomes ever documented through a supply chain intervention.

Data confirms a staggering 56 percent reduction in maternal mortality and a 42 percent decrease in zero-dose prevalence.

Zipline is the most cost-effective immunisation intervention and one of the most cost-effective maternal health interventions on record.

Beyond these clinical milestones, the system serves as a powerful engine for economic stability.

“By creating hundreds of local jobs and safeguarding the health of the workforce, it generates tens of millions in annual economic growth, proving that a resilient supply chain is the essential foundation for a thriving society,” Kayitana closes.

The post Zipline Rwanda : Autonomous Delivery Across Rwanda appeared first on Healthcare Outlook.

MENTAL HEALTH MATTERS

Mental health is deeply connected to every aspect of a person’s life, from physical health to relationships, education, and workforce productivity.

Promoting it is therefore critical, especially amid the ongoing mental health crisis in the US, for which Mental Health Awareness Month serves as an important reminder each May.

However, the reality is that mental health and wellness should be a national priority every single day.

Meaningful progress has been made in reducing the stigma surrounding mental health issues, but too many individuals and families still face barriers to accessing care or feel hesitant to seek help.

“National awareness efforts play a vital role in normalizing conversations, encouraging early intervention, and reinforcing the importance of evidence-based mental health care,” emphasizes Brian Setzer, Chief Executive Officer of Newport Healthcare (Newport) – a leading provider of evidence-based behavioral health treatment for youth, young adults, and families.

“At a broader level, promoting mental wellness strengthens communities; when people have access to the right support at the right time, outcomes improve for individuals and families. Mental Health Awareness Month helps shine a light on that collective responsibility and the work that still needs to be done.”

Newport supports Mental Health Awareness Month by sharing resources throughout May with its audience of mental health professionals, past and current patients, and families.

The company conducts continuing education webinars and promotes the awareness month on its social media channels to highlight specific mental health trends and share inspirational stories of hope.

Various events are also held at Newport programs across the country for employees and patients to celebrate mental health and well-being.

“But really, every month is Mental Health Awareness Month at Newport,” acknowledges Setzer.

“We are focused year-round on sharing information, reducing stigma around treatment, and increasing access to care for young people and families.”

CONTINUUM OF CARE

The full continuum of care at Newport includes nationwide residential services, partial hospitalization programs (PHPs), and intensive outpatient programs (IOPs) for mental health and substance use disorders, as well as psychiatric inpatient services.

Newport’s family-centered, integrated approach fosters sustainable healing from a foundation of compassionate care and clinical expertise.

“Our stated mission is to provide results-driven, clinically integrated behavioral healthcare to individuals and families – creating hope, sustainable healing, and resiliency,” Setzer outlines.

Newport’s vision is to be the transformative leader in behavioral healthcare, focused on increasing access, driving innovation, and fostering authentic connections that inspire hope.

The company currently has residential treatment programs in eight states: California, Connecticut, Massachusetts, Minnesota (MN), North Carolina, Utah, Virginia, and Washington.

It also has outpatient treatment programs in each of those states, along with Georgia, Maryland, Pennsylvania, and Wisconsin, as well as an inpatient hospital in Brooklyn Park, MN.

“We have over 3,500 dedicated employees across the US. Our workforce of skilled and compassionate individuals is integral to the important, life-changing work we do,” Setzer says.

INNOVATIVE TECHNOLOGIES

Newport has expanded into new markets and added to its service offerings over the past few years.

This includes developing a learning health system, using valuable data gathered over many years to improve care quality as the company grows – by infusing best practices at scale and improving reliability in its outcomes.

“We continue to expand our service offering with a commitment to excellence and leading with innovation as patient needs evolve in each region across the US,” affirms Jameson Norton, MBA, FACHE, Chief Operating Officer.

Moreover, Newport is leaning into various technologies both in the delivery of care and the care itself.

For adult patients with treatment-resistant depression, the company’s PrairieCare division in Minnesota has deployed transcranial magnetic stimulation (TMS), a US Food and Drug Administration (FDA)-approved intervention that gives patients who have struggled for years an opportunity for relief.

Newport’s outcomes data shows that more than half of their TMS patients experience 50 percent improvements in their depression symptoms.

“We have also built out technologies that allow us to analyze data, patterns, and outcomes, providing us with tailored approaches to treatment at the individual level,” says Chief Innovation and Optimization Officer, Dr. Brent Nelson, MD.

In addition to offering innovative services like TMS, Newport is embracing the artificial intelligence (AI) revolution – to assist rather than replace humans.

“There is more demand for mental health services than can be possibly managed by our existing workforce. We must work smarter to be able to let our workforce focus on human connection, interaction, and healing, and use our AI assistants to help us get the busy work of healthcare accomplished in automated ways,” insights Nelson.

“We can deploy innovations around data gathering, writing documentation, providing assistants to facilitate real-time, continuous communication, and automated tracking of things that need to be accomplished in the context of care.”

The goal is to make the experience even more of a human connection, with AI working in the background to ensure Newport is meeting the highest levels of quality and safety.

This has also provided the company with significant insight into its data around outcomes and measures.

“In the past, it would have taken an army of statisticians to manage and analyze our data. Now, with AI assistants, we can put that power directly in the hands of our healthcare experts to allow them to find actionable patterns in their data,” Nelson enthuses.

CLINICAL COMPLEXITY

Mental health treatment is not one-size-fits-all, and the populations Newport serves are increasing in clinical complexity.

“Expanding our capabilities allows us to meet people where they are, with care that is clinically appropriate and proven to be effective,” Norton notes.

As the demand for mental health services continues to grow, so does the responsibility to ensure care is accessible and adaptable.

That means investing in a full continuum of care, developing specialized programming, and being intentional about addressing gaps that have historically limited access to quality treatment.

“Accessibility and affordability are essential to expanding care in this country. Whereas mental health treatment 15 years ago was prominently private pay – meaning it was paid directly out of pocket by families – they are increasingly turning to their insurance provider to pay for care,” observes Norton.

“Partnering with insurance providers helps families access quality healthcare much more easily. We currently accept most major insurances and are actively adding more – this is a priority for families and for Newport.”

Adapting to the changing mental health landscape in the US is essential. The needs of children, teenagers, and young adults are evolving rapidly, influenced by factors like technology, social dynamics, academic pressure, and broader societal uncertainty.

At the same time, there is increased acuity, earlier onset of symptoms, and more complex co-occurring conditions.

“If we don’t evolve alongside those changes and diversify our capabilities, we risk falling short of what patients and families truly need,” Norton warns.

“That means continuously reassessing how care is delivered, expanding access points, and integrating new, evidence-based approaches that reflect both clinical advancements and real-world challenges.”

This also requires a willingness to listen to patients, families, and clinicians on the front lines and use that insight to inform innovation.

Whether it’s enhancing specialized programming, strengthening early intervention, or leveraging data to guide treatment, adaptability is what allows Newport to stay effective and relevant.

“By staying responsive to the changing mental health landscape, we can ensure the care we provide remains impactful, accessible, and aligned with the realities families are facing right now,” Norton sets out.

OUTCOMES RESEARCH

Newport is proud of its focus on measurement-based care programs and long-standing commitment to outcomes research.

The company has a dedicated Center for Research and Innovation focused on tracking and analyzing its treatment outcomes.

Recent data highlights the effectiveness of the company’s treatment programs, showing patients experience measurable improvements in depression, anxiety, suicide risk, well-being, family attachment, general functioning, and other measures.

“Independently reviewed by a third-party academic consultant, this research is evidence that our comprehensive treatment model creates transformative, lasting results for adolescents and young adults in both residential and outpatient care,” acclaims Norton.

“Outcomes studies are essential because they ensure we’re not just providing care – we’re delivering care that truly makes a difference.

“In behavioral healthcare, it’s critical to move beyond intention and rigorously measure impact. Our outcomes data allows us to evaluate what’s working, identify opportunities to improve, and hold ourselves accountable to the patients and families we serve,” he adds.

The data is used to inform every aspect of treatment and helps Newport to refine clinical models, tailor interventions to better meet the needs of specific populations, and ensure its approaches are grounded in evidence.

This continuous feedback loop allows the company to adapt in real time and stay aligned with best practices in the field.

“We also track how patients are doing after they leave our care, and we can see they maintain improvements months later and are functioning better in multiple aspects of their daily lives, such as relationships, school, work, and family connection,” Norton states proudly.

Just as important, outcomes data builds trust. For families making incredibly important decisions about care, having transparency into proven results provides confidence that they are choosing a program dedicated to quality, accountability, and long-term success.

“Ultimately, our focus on outcomes is about ensuring every young person who comes to us has the best possible opportunity to heal and thrive,” Norton says.

SPECIALIZED OCD CARE

For children and adolescents struggling with obsessive-compulsive disorder (OCD), Newport has developed specialized care, recognizing both the complexity of the condition and profound impact it can have on a young person’s development and daily life.

About 20 percent of people with OCD experience onset at age 10 or earlier. It is also often misunderstood or misdiagnosed, which can delay effective treatment, so early identification and the right clinical approach are critical.

“Our programs are grounded in evidence-based practices, particularly exposure and response prevention (ERP) therapy, which is widely considered the gold standard for treating OCD,” Norton tells us.

“What sets our approach apart is how we integrate this modality into a broader, individualized treatment plan that also addresses co-occurring conditions, family dynamics, and the unique developmental needs of each patient.”

Newport also places a strong emphasis on family involvement, equipping parents and caregivers with the tools and understanding they need to support their child’s progress outside of treatment.

“Ultimately, our goal is not just symptom reduction, but helping young people regain a sense of control, confidence, and the ability to fully engage in their lives,” he assures.

CLINICALLY CREDIBLE

Clearly, Newport is uniquely positioned to serve adolescents and young adults on a national basis across the full continuum of care.

“We are heavily focused on refining our care delivery models to create a partnership with our patients, their families, and their insurance providers to ensure treatment accessibility, affordability, and best-in-class outcomes,” Setzer informs us.

Looking ahead, the company is committed to improving timely and efficient access to care in every market while advancing its clinical outcomes and its position as a trusted and clinically credible leader in behavioral healthcare.

“Part of fulfilling this promise is ensuring Newport is a great place to work for our employees, allowing them to grow as professionals in our team-based care model, career ladders, and training opportunities,” Norton shares.

Newport’s central focus is to deliver the highest quality of care through understanding and respect for the individual’s journey.

“We utilize deep connections, team-based approaches, and focused treatments based on modern, research-proven techniques,” Nelson closes.

“The goal is to get the individual back to health and back to their life in a way that supports their full recovery.”

The post Newport Healthcare : Mental Health Matters appeared first on Healthcare Outlook.

SLEEP ON DEMAND

Foundational to both physical and emotional health, sleep is crucial to the ability to perform at your best. Not only does it play a critical role in cognitive functions, but it also aids in tissue repair, muscle growth, and immune system strengthening – making high-performance sleep essential for overall well-being.

Elemind is here to help people take back control of their sleeping patterns.

As a neurotechnology company building the first clinically validated, non-invasive platform that can read and write to the brain in real-time, Elemind combines advanced neuromodulation algorithms and artificial intelligence (AI) to guide the brain from one state to another just using acoustic neurostimulation.

“We launched commercially in 2024 with a wearable electroencephalogram (EEG) headband designed to help people fall asleep and fall back to sleep significantly faster without drugs,” introduces Meredith Perry, co-Founder and CEO.

“Whereas every other wearable just reads, Elemind reads and writes. We don’t just track the brain – we change it directly,” she asserts.

Elemind’s industry-changing product is built on direct, real-time interface with the brain. Using high-fidelity EEG, the company continuously reads neural activity and applies precisely timed acoustic stimulation individualized to each person’s brain dynamics.

The system models a user’s neural state moment by moment and intervenes at exactly the right phase of ongoing brain activity. This closed-loop approach, grounded in peer-reviewed clinical research and protected by patents, allows Elemind to influence sleep at the level where it naturally occurs – the brain itself.

The company views this as a new class of non-invasive medicine, one that uses sound, timing, and neuromodulation to produce measurable physiological effects.

“Elemind is building infrastructure, not a gadget,” emphasizes Perry.

“We are laying the foundation for how humans will interact with their own brains safely, non-invasively, and intelligently. Sleep is where that journey begins, but it’s not where it ends.”

THE FUTURE OF SLEEP

Elemind has pioneered a practical, wearable implementation of closed-loop neuromodulation, combining high-fidelity EEG, low-latency signal processing, AI, and precisely phase-locked acoustic stimulation in a consumer-ready device.

“Critically, our stimulation is not static. It is timed to the user’s own brainwaves, down to the millisecond,” Perry details.

This real-time phase targeting allows Elemind to influence sleep onset and other neural transitions effectively and is supported by multiple peer-reviewed studies. No other consumer-available system operates at this level of temporal and physiological precision.

The company is demonstrating that sleep can be treated as a modifiable neural process rather than something one merely observes or sedates.

“By gently intervening at the right time, we can help people fall asleep faster, improve sleep continuity, and potentially enhance deeper stages of sleep without pharmaceuticals,” expands Perry.

Beyond sleep quality, the implications include better next-day performance, improved recovery, and reduced reliance on sleep medications. More broadly, Elemind is helping shift health and wellness toward targeted, non-invasive, and adaptive interventions.

BEYOND SLEEP

Elemind’s vision of ‘beyond sleep’ exemplifies its ambition to unlock the brain’s potential, pushing the boundaries of what’s possible in neurotechnology and sleep science.

“Sleep is our entry point, not our endpoint. We chose sleep because it gives us long, high-quality neural data every night and a clinically meaningful problem where real-time modulation matters,” Perry informs.

Beyond sleep, the vision is a platform for the brain. Clinical trials using Elemind’s technology show efficacy in improving memory consolidation, recovery, neurological disorders such as tremors, and other brain state-dependent conditions.

Long-term, Elemind is building an adaptive neural system that learns from each interaction with the brain and improves over time.

To achieve this, the company is working on a variety of projects to expand its capabilities. One such initiative is the Deep Sleep Stimulation, which builds on Elemind’s work on sleep onset and targets slow-wave activity during rest. Its goal is to enhance sleep depth and the brain’s natural restorative and memory-related processes.

“This work is also being extended into clinical research. We recently received a USD$6.3 million grant from the Medical Research Council (MRC) to study how enhancing deep sleep may support memory consolidation in people with dementia,” details Perry.

“It’s an important step in understanding how targeted, non-invasive brain modulation during sleep could have meaningful neurological benefits beyond sleep quality alone.”

WHERE THE JOURNEY BEGINS

Elemind is proudly built by a small, deeply technical team that spans neuroscience, electrical engineering, machine learning (ML), and applied clinical research. The team includes industry engineers and world-class academic collaborators, and has multiple peer-reviewed clinical trials published in top scientific journals.

Its scientific co-Founders include Dr. Ed Boyden from the Massachusetts Institute of Technology (MIT), a pioneer in neurotechnology, and Dr. Nir Grossman from Imperial College London, whose work has helped define modern non-invasive brain stimulation.

Co-Founder and CTO, Dr. David Wang, also holds a PhD in AI from MIT and leads the development of the company’s real-time neural modeling and closed-loop systems.

“I come from a background in astrobiology and wireless power, which has helped shape how we think about building precise, scalable technology for complex biological systems,” explains Perry.

Elemind also works closely with Dr. Heather Read, a professor at the University of Connecticut, whose expertise in sleep and neurophysiology informs the company’s clinical direction.

Supporting the science behind Elemind is a lean, highly effective team of engineers, operations leaders, and marketers who focus on translating rigorous research into products people can actually use.

“Together, our team is pushing the boundaries of what non-invasive neurotechnology can do, while staying grounded in real-world impact,” prides Perry.

As Elemind continues to look ahead towards a successful future of promoting deep, regenerative sleep, its priorities comprise expanding clinical validation, launching new sleep-stage specific features, and scaling access to the technology responsibly.

“We are also deepening partnerships across healthcare, wellness, and performance, while investing heavily in our core neuromodulation platform,” she concludes.

The post Elemind : Sleep On Demand appeared first on Healthcare Outlook.

AI-DRIVEN ADVANCEMENT IN PARKINSON’S CARE

Cellular Intelligence has entered into an agreement with Novo Nordisk to acquire global rights to the pharmaceutical giant’s clinical-stage cell therapy programme for Parkinson’s disease.

The agreement marks a significant milestone for Cellular Intelligence as it looks to apply its proprietary AI-native platform to accelerate clinical development, manufacturing, and the path towards commercialisation for the programme, which is currently in a first-in-human Phase 1/2 clinical trial.

Importantly, the therapy has already received FDA Fast Track Designation and IND clearance for further clinical development, underscoring its potential as a meaningful disease-modifying treatment for people living with Parkinson’s disease.

As part of the arrangement, Novo Nordisk will also make an equity investment into Cellular Intelligence and remain eligible for future milestones and royalties.

SCALING CELL THERAPY THROUGH AI

At the centre of the collaboration is Cellular Intelligence’s AI-native platform, which combines proprietary multiplexing technologies with a foundation model trained on data spanning millions of unique perturbation conditions.

The company believes this approach can significantly compress traditional cell therapy development and manufacturing timelines whilst reducing costs and improving scalability – key barriers that have historically limited wider commercial adoption within regenerative medicine.

The Parkinson’s programme itself focuses on an allogeneic pluripotent stem cell-derived dopaminergic progenitor therapy, designed to address the growing global burden of neurodegenerative disease.

Beyond the immediate programme, Cellular Intelligence also expects the clinical and manufacturing data generated through development to further strengthen its foundation model, potentially enabling wider applications across cell therapy and regenerative medicine in the future.

STRENGTHENING CLINICAL LEADERSHIP

To support the programme’s continued advancement, Cellular Intelligence has appointed Nuno Mendonça, M.D., as Chief Medical Officer.

A board-certified neurologist, Dr. Mendonça brings extensive experience from senior clinical development roles at Bial, AbbVie, and Novartis Gene Therapies, spanning both early- and late-stage neuroscience and rare disease programmes across North America and Europe.

The appointment reflects Cellular Intelligence’s ambitions to rapidly scale the programme’s clinical progression whilst leveraging its AI capabilities to streamline manufacturing and operational efficiency.

Operating under the legal entity Somite Therapeutics, Cellular Intelligence describes itself as an AI-native TechBio focused on building a universal foundation model of cell signalling to better understand, predict, and ultimately control cellular behaviour.

Headquartered in Boston, the company has raised more than USD$60 million to date from investors including Khosla Ventures, CZI, SciFi VC, and AMD Ventures, as it continues expanding its clinical-stage regenerative medicine platform.

The post Novo Nordisk and Cellular Intelligence Advance Parkinson’s Therapy appeared first on Healthcare Outlook.

Lilly Increases Indiana Manufacturing Commitments to More Than $21 Billion

The latest commitment brings Lilly’s total Indiana capital expansion investment since 2020 to more than $21 billion, reinforcing the company’s long-term focus on scaling U.S.-based pharmaceutical production capacity to support growing demand for advanced therapies and metabolic disease treatments.

The investment will support expanded capabilities at Lilly Lebanon API, one of the company’s future active pharmaceutical ingredient production facilities, and Lilly Lebanon Advanced Therapies, which officially opened this week.

Genetic Medicine Facility Marks New Phase in Advanced Therapy Manufacturing

Lilly Lebanon Advanced Therapies is the company’s first dedicated manufacturing facility focused on genetic medicines.

The site is designed to support both clinical and commercial-scale production of therapies targeting disease at the genetic level, including a range of advanced treatment modalities from early-stage development through large-scale supply.

According to Lilly, designing the facility required the development of new manufacturing processes without established commercial precedent, highlighting the growing complexity of next-generation pharmaceutical production infrastructure.

The facility is the first of three planned manufacturing sites on the Lebanon campus, which will also include Lilly Lebanon API and the Lilly Medicine Foundry.

Expanded Capacity Supports Obesity and Diabetes Drug Production

The Lebanon API site is expected to manufacture several of Lilly’s key metabolic disease products, including:

• Zepbound® (tirzepatide) for weight management
• Mounjaro® (tirzepatide) for type 2 diabetes
• Foundayo™ (orforglipron), Lilly’s FDA-approved once-daily weight loss pill
• Retatrutide, an investigational obesity and cardiometabolic therapy currently in late-stage development

When completed, the Lebanon API facility is expected to become the largest API production site in U.S. history.

“From genetic medicines that could one day prevent disease at its source, to Foundayo, a pill making weight loss treatment accessible to millions, we are not just discovering the medicines of the future—we are building the world’s most advanced plants to make them,” said David A. Ricks, Lilly chair and CEO.

Pharmaceutical Manufacturing Expansion Strengthens U.S. Supply Chain Strategy

The announcement reflects broader industry efforts to strengthen domestic pharmaceutical manufacturing capacity and reduce supply chain risk through increased U.S.-based production.

U.S. capital expansion commitments since 2020 now total more than $50 billion, supported by policies promoting domestic manufacturing investment and the company plans to begin construction on several newly announced U.S. manufacturing facilities later this year.

Indiana Governor Mike Braun said the investment reinforces the state’s position within the life sciences manufacturing sector.

“With this investment in Lebanon and across the state, Indiana is reinforcing its position as a prime destination for life sciences and advanced manufacturing, spanning innovation, production and global distribution,” Braun said.

Manufacturing Investments Deliver Broader Economic Impact

According to findings from an upcoming Indiana University Kelley School of Business report cited by Lilly, the company accounts for 70% of Indiana’s pharmaceutical GDP, with every Lilly job supporting more than two additional jobs statewide.

Lilly also estimates that every dollar it spends locally generates up to four dollars in additional regional economic activity.

The Lebanon manufacturing campus has become a central component of Lilly’s domestic production strategy as pharmaceutical companies continue increasing investment in advanced biologics, obesity therapies, and next-generation genetic medicines.

“Lilly’s sustained investments since 2020 underscore the growing strength of Indiana’s life sciences sector,” said Indiana University President Pamela Whitten. “Progress at this scale is possible only through robust partnerships.”

The post Eli Lilly Expands North America Indiana Manufacturing Investment with Genetic Medicine Facility appeared first on Healthcare Outlook.

Wearables Move Further into Preventive Healthcare

Samsung Electronics has announced the results of a joint clinical study with Chung-Ang University Gwangmyeong Hospital demonstrating the potential for smartwatch-based prediction of vasovagal syncope (VVS), commonly known as fainting.

The research used biosignal data collected from the Samsung Galaxy Watch6 and analysed heart rate variability patterns through an AI algorithm to identify signs of an impending fainting episode.

According to the study, the model was able to predict episodes up to five minutes in advance with an accuracy rate of 84.6%.

Addressing Risks Associated with Vasovagal Syncope

Vasovagal syncope occurs when heart rate and blood pressure suddenly drop, often triggered by stress or other physiological factors, leading to temporary loss of consciousness.

While fainting itself is generally not life-threatening, falls associated with episodes can result in serious secondary injuries, including fractures and concussions.

“Up to 40% of people experience vasovagal syncope over their lifetime, with one-third experiencing recurrent episodes,” said Junhwan Cho, Professor of Cardiology at Chung-Ang University Gwangmyeong Hospital.

“An early warning could give patients advance time to get into a safe position or call for help, which would dramatically reduce the incidence of secondary injuries.”

Clinical Validation Using Consumer Wearables

The study evaluated 132 patients with suspected VVS symptoms during induced fainting tests.

Researchers used the smartwatch’s photoplethysmography (PPG) sensor to collect heart rate variability data, which was then processed through an AI model trained to detect physiological changes preceding fainting episodes.

The system achieved a clinically meaningful sensitivity of 90% and specificity of 64%, supporting the feasibility of wearable-based prediction systems in healthcare settings.

Samsung said the findings represent the first study to demonstrate the potential for a commercial smartwatch to provide early prediction of syncope.

Expanding the Role of Digital Health Monitoring

The findings reflect a broader trend toward integrating consumer-grade wearable devices into preventive healthcare and remote patient monitoring strategies.

“This study is an example of how wearable technology can help shift healthcare from being designed for ‘post-care’ to a model of ‘preventive care,’” said Jongmin Choi, Head of Health R&D Group at Samsung’s Mobile eXperience Business.

“We are committed to driving technological innovation that empowers our users to lead healthier everyday lives.”

Real Implications for Healthcare Providers

For healthcare providers, the study suggestss the increasing clinical potential of wearable biosignal monitoring in early intervention and patient safety applications.

The ability to identify high-risk events before symptoms escalate could support new models of remote monitoring, particularly for patients with recurrent syncope conditions or elevated fall risk.

For digital health developers, the research also adds the growing convergence of AI analytics, biosensors and consumer devices in preventive care pathways.

The post Can a Smart Watch Predict Fainting? Samsung Study Demonstrates Preventative Healthcare Tech Solution appeared first on Healthcare Outlook.

This is a working conference. Less theory, more application. Expect practical insight on how omnichannel strategy is actually being executed across global and local markets – with measurable impact.

Conference: Pharma Omnichannel Excellence
Date: 3rd June 2026
Venue: One America Square, London

WHAT THIS EVENT IS BUILT AROUND

The agenda is tightly aligned with the challenges pharma teams are actively dealing with:

• AI-powered omnichannel transformation
  Practical use of AI to improve targeting, forecasting, and decision-making
• Hyper-personalisation and precision segmentation
  Balancing relevance with compliance in HCP and patient engagement
• Data, measurement, and ROI
  Moving beyond surface metrics to demonstrate commercial impact
• Global vs local execution
  Aligning central strategy with regional realities and compliance constraints
• Content that connects
  Delivering consistent messaging across face-to-face, digital, and emerging channels
• Social media in pharma
  Navigating compliance while maintaining authenticity and engagement
• Customer feedback loops
  Turning insight into continuous improvement across channels

FORMAT AT A GLANCE

• 25+ speakers from pharma marketing, commercial, and medical teams
• 3 panel discussions tackling shared industry challenges
• 9 international perspectives shaping global strategy
• 2+ hours of networking built into the day
• Interactive Q&A and live polling throughout

This isn’t a passive sit-and-listen setup. It’s designed for participation and peer exchange.

WHY IT MATTERS

Omnichannel in pharma has moved past experimentation. The pressure now is on execution, measurement, and proving ROI.

This event focuses on:

• Connecting strategy to real-world delivery
• Aligning internal teams across commercial, marketing, and medical
• Understanding how AI and data are reshaping engagement models
• Building approaches that stand up to compliance scrutiny

For most teams, this is where friction sits. That’s what this conference is addressing.

WHO SHOULD ATTEND

• Pharma marketing leaders
• Commercial strategy teams
• Medical affairs professionals
• Digital and omnichannel specialists

If your role touches customer engagement, channel strategy, or performance measurement, this is directly relevant.

COMMERCIAL AND NETWORKING VALUE

• 97% satisfaction rate from the previous event
• Access to senior decision-makers across pharma
• Peer-led discussions with no sales pitches from the stage
• Real case studies with implementation detail

It’s positioned as a high-density day – insight, connections, and takeaways without wasted time.

OPPORTUNITIES TO GET INVOLVED

There are multiple ways to participate beyond attending:

• Speaking opportunities
• Sponsorship and exhibition packages
• One-to-one meetings with attendees

This is particularly relevant for organisations supporting pharma with technology, data, or marketing solutions.

REGISTRATION AND GROUP OFFERS

Group bookings are incentivised:

• Send 4 delegates for the price of 3
• Or 3 delegates with the third at half price

(Available for in-house pharma teams)

CONTACT DETAILS

For attendance, partnerships, or further information:

• https://pharmamarketingconference.com
• +44 (0)20 3479 2299
• info@pharmamarketingconference.com

ABOUT THE ORGANISER

Delivered by Global Insight Conferences, a specialist in industry-led events designed around practical value and high-quality networking.

If you’re working on omnichannel strategy in pharma right now, this sits firmly in the “useful day out of the office” category rather than a generic conference slot.

The post Pharma Omnichannel Excellence Conference | 3rd June 2026 | London appeared first on Healthcare Outlook.

Written in collaboration with patients, advocacy groups, and the pharmaceutical industry, the event is designed to explore how organisations can improve patient experiences, strengthen trust, and deliver meaningful healthcare outcomes through more collaborative and responsive engagement strategies.

Conference: Patient Centricity & Engagement Conference
Date: 24th June 2026
Venue: The Grand Connaught Rooms, London

Defining the Future of Patient-Centric Innovation

As healthcare organisations continue to navigate rapid technological change, increasing patient expectations, and growing pressure to demonstrate measurable impact, patient centricity has become a critical strategic priority across the pharmaceutical industry.

This year’s conference agenda focuses heavily on actionable engagement strategies, AI adoption, patient feedback integration, and multi-stakeholder collaboration.

Topics set to dominate discussions include:

• AI in patient engagement and patient experience strategies
• Patient trust and transparency
• Patient involvement in HTA processes
• Engagement in clinical trials and treatment pathways
• Measuring the real impact of patient engagement
• Advocacy collaboration and stakeholder alignment
• Internal transformation to embed patient-first thinking

The conference aims to move beyond theory and provide attendees with practical insights they can apply directly within their organisations.

AI, Trust, and the Next Phase of Patient Engagement

One of the major themes for 2026 will be how pharmaceutical organisations can strategically integrate AI into patient engagement without compromising trust, empathy, or accessibility.

Dedicated sessions will examine:

What meaningful AI-driven patient engagement should actually look like
How to balance innovation with ethical considerations
Using technology to personalise engagement while reducing patient burden
Building systems that listen and adapt to real patient needs

Alongside technology discussions, the event will also focus on restoring and strengthening patient trust through better communication, earlier collaboration, and more inclusive engagement models.

Interactive Panels and Real-World Perspectives

The conference programme includes four interactive panel discussions covering:

• Patient Perspectives in Treatment
• Patient Engagement in Clinical Trials
• Patient Involvement in HTA
• Stakeholder Collaboration

Attendees will hear directly from patients and advocacy groups about their experiences interacting with industry, what they believe still needs to improve, and where genuine opportunities for collaboration exist.

More than 10 patient representatives and advocates are expected to participate across the agenda.

Industry Speakers and Case Studies

The event will feature fresh case studies and insights from organisations including:

• Bristol Myers Squibb
• Ipsen
• Bayer
• Jazz Pharmaceuticals
• Pfizer
• Macmillan Cancer Support

Organisers describe the event as a practical, discussion-led environment focused on genuine learning rather than sales presentations.

Networking and Collaboration Opportunities

In addition to the conference sessions, attendees will benefit from two hours of dedicated networking opportunities designed to encourage meaningful connections across the patient engagement ecosystem.

Who is the conference for?

The event attracts professionals working in:

• Patient engagement
• Patient advocacy
• Medical affairs
• Commercial strategy
• Market access
• Clinical operations
• Patient experience
• Digital health and engagement

Group discounts are available for organisations sending multiple delegates.

Partnership and Sponsorship Opportunities

Companies interested in increasing visibility within the patient engagement and pharmaceutical space can also explore sponsorship, exhibiting, speaking, and one-to-one meeting opportunities.

Packages include exhibition stands with delegate passes and networking access throughout the event.

REGISTRATION AND GROUP OFFERS

Group bookings are incentivised:

• Send 4 delegates for the price of 3
• Or 3 delegates with the third at half price

(Available for in-house practitioners only) More details

Contact Details

• patientengagementconference.com
• +44 (0)20 3479 2299
• partner@patientengagementconference.com

The post Patient Centricity & Engagement Conference | 24th June 2026 | London appeared first on Healthcare Outlook.

TURBOCHARGE YOUR MARKETING WITH BUILT-IN TOOLS

Reaching the right clients at the right time can make or break your revenue goals. Integrated marketing tools give you direct access to your client base through email campaigns, SMS promotions and re-engagement messages.

Instead of paying for separate marketing platforms, you can launch targeted campaigns from the same system that manages your appointments and client data.

The salon industry is expected to grow by 7.90 percent annually, on average, through 2034. Capturing your share of that growth means staying visible to both current and potential clients. Built-in marketing tools let you announce new services, share seasonal promotions and remind clients it’s time for their next appointment.

When you can use software to get more salon clients through integrated campaigns, you keep more of your marketing budget working directly for your business.

DRIVE REPEAT BUSINESS WITH MEMBERSHIP OR LOYALTY PROGRAMS

One-time clients pay the bills, but loyal regulars build sustainable revenue. Many salon software platforms allow the creation of loyalty or membership programs that reward clients automatically based on dollars spent or visits completed. Every service they book earns points toward their next treatment or retail purchase.

Traditional punch cards require manual tracking and often get lost or forgotten. Automated programs eliminate that friction entirely. Your software tracks every transaction and applies rewards seamlessly.

Clients can see their progress through your booking portal, and they’re more motivated to return when they’re close to earning their next reward. This creates a predictable cycle of repeat visits that stabilizes your revenue month after month.

INCREASE AVERAGE SALES WITH ONLINE ADD-ONS

Industry experts recommend that salons allocate about 3 percent of gross income to marketing. Smart salon software to increase profit often includes built-in e-commerce for add-ons and gift cards, helping you maximize the return on that investment

For example, the software may suggest complementary services during the online booking process. A client scheduling a haircut sees an option to add a deep conditioning treatment or scalp massage with a single click.

These low-friction upsells happen before the client ever walks through your door. The same principle applies to gift card sales as add-ons during booking. This can turn your website into a revenue generator even when your salon is closed.

MAXIMIZE YOUR BOOKINGS WITH OPTIMIZED SCHEDULING

Keeping your calendar full protects revenue that empty chairs lose. Advanced scheduling features meet clients where they are. People book appointments when the idea occurs to them, whether that’s late at night or early Sunday morning when your salon is closed.

Software with online booking capabilities lets clients secure their spot at any time of day or night. You get more salon clients with 24/7 software because you capture every opportunity regardless of business hours.

Smart calendar management identifies gaps in your schedule and can suggest optimal booking times to keep your team consistently busy. Every hour your professionals spend working instead of waiting translates directly into higher revenue.

Meanwhile, automated reminders can also reduce no-shows by sending confirmations via text or email before each appointment.

OFFER FLEXIBLE AND CONVENIENT PAYMENT METHODS

The checkout experience shapes how clients remember their visit. Software that integrates modern payment options makes transactions smooth and effortless.

Contactless payments, mobile wallets and securely saved payment cards let clients complete their purchase in seconds.

Faster checkout frees your team to dedicate more time to the next client. When the payment experience feels convenient and current, clients associate that positive feeling with your entire brand. They’re more likely to rebook and recommend your salon to friends when every touchpoint feels professional and easy.

TAKE CONTROL WITH SMART INVENTORY MANAGEMENT

Retail products and professional inventory represent significant capital investment. Poor inventory management ties up cash in slow-moving stock while popular items run out at the worst possible time.

Many software platforms offer smart inventory features that track product usage in real time and can automatically trigger reorder alerts when supplies run low.

You can identify which retail products generate profit and which ones sit on shelves collecting dust. This is an often-overlooked way that salon software can increase profit.

When your bestselling products are always in stock, and your capital focuses on items that move, your retail revenue becomes a reliable profit centre.

RECLAIM YOUR TIME THROUGH SMART TASK AUTOMATION

Every hour your team spends manually calculating payroll, compiling sales reports or confirming appointments is time they could spend with paying clients.

Task automation handles routine processes in the background. Payroll calculations happen automatically based on hours worked and commission structures.

Sales reports are generated on schedule while appointment confirmations are sent at the optimal time.

When you free your team from repetitive administrative tasks, they can reinvest that time in activities that actually drive revenue. Your managers can focus on business strategy, and your stylists can take more appointments.

ELIMINATE BOTTLENECKS THROUGH RESOURCE MANAGEMENT

Maximizing your team’s productivity matters, but physical resources can create bottlenecks just as easily as staffing constraints. Treatment rooms, specialised equipment and even shampoo stations become limiting factors when demand exceeds availability.

Resource management features let you track and allocate these physical assets alongside your team’s schedules. You can see at a glance when your most popular treatment room is available or when your high-demand massage equipment is booked.

This visibility helps you schedule more strategically and serve more clients. Every additional client you can accommodate because resources are optimized properly adds directly to your revenue.

HOW MEEVO DRIVES REVENUE FOR SUCCESSFUL SALONS AND SPAS

Meevo combines all of these features into a single platform built specifically for salons, spas and med spas. Salon leaders report excellent results.

That’s the kind of measurable impact that transforms salon software to increase profit from a nice-to-have into a strategic necessity.

The platform has won Beauty Launchpad’s “Best Salon Software” award 19 times and offers more than 150 industry-leading reports that give you complete visibility into your business performance.

From HIPAA-compliant features for med spas to yield management tools that adjust pricing based on demand, Meevo delivers the comprehensive capabilities that successful salon and spa owners need to compete and grow.

FREQUENTLY ASKED QUESTIONS ABOUT SALON SOFTWARE

1. What is the most important feature in salon software?
   It depends on your specific business goals and current challenges. However, robust reporting and analytics capabilities are universally valuable. Measurement drives improvement and detailed reports help you understand where growth opportunities exist.
2. How much should I expect to pay for salon software?
   Pricing varies significantly across the market. Some basic platforms offer free plans with limited features, and most offer tiered pricing according to your business size or number of locations.  Focus on return on investment rather than the price tag alone. Salon software that increases profit typically pays for itself many times over.
3. How can salon software help with employee burnout?
   Service industry professionals are prone to burnout from emotional labor and the constant demands of client interaction. Software that automates tedious administrative tasks reduces the cognitive load on your team. When staff members spend less time on backend paperwork and scheduling logistics, they experience less stress and can focus their energy on the creative, rewarding aspects of their work.

STYLING YOUR PATH TO PROFITABILITY

The right software represents an investment in sustainable growth. From marketing tools and loyalty programs to optimized scheduling, flexible payments, inventory control, resource management and task automation, there are many ways you can use software to get more salon clients and increase revenue from existing ones.

The salon and spa industry rewards businesses that combine exceptional service with operational excellence. Strategic software helps you achieve both.

The post Meevo : How the Right Software Can Drive Revenue Growth for Your Business appeared first on Healthcare Outlook.

ENABLING PHARMACEUTICAL SUPPLY CHAIN VISIBILITY

As demand for glucagon-like peptide-1 (GLP-1) therapies accelerates and direct-to-patient delivery becomes more common, pharmaceutical cold chains are being pushed into more complex and fragmented distribution models.

What was once a tightly controlled and highly predictable system is now under pressure from increased shipment volumes, more handoffs, and greater exposure to uncontrolled environments, particularly in the final stages of delivery.

For therapies that require strict temperature control and careful handling, this shift is exposing critical gaps in visibility and accountability.

Temperature excursions, handling inconsistencies, and limited oversight in the last mile can all compromise product integrity, while the rise of compounded alternatives is placing even greater emphasis on authentication and traceability at the item level.

Deepak Prakash, Vice President, Healthcare at Identiv, outlines how the company is helping address these challenges through sensor-enabled Bluetooth Low Energy (BLE) smart labels and digital identity solutions that bring continuous, item-level visibility to pharmaceutical logistics.

By enabling products to communicate their condition, movement, and provenance in real time, Identiv is helping manufacturers and logistics providers move beyond retrospective cold chain monitoring toward a more connected, intelligent, and accountable model.

Healthcare Outlook (HO): As the demand for GLP-1 doses continues to surge and the frequency of direct-to-patient delivery increases, what specific vulnerabilities has this shift exposed in the cold chain?

Deepak Prakash, Vice President, Healthcare (DP): The rapid adoption of GLP-1 therapies is reshaping how high-value pharmaceuticals move through the supply chain.

What was once a tightly controlled and predictable system now operates across a broader mix of environments, handoffs, and delivery models, including channels that reach patients directly.

That expansion is being driven by pure scale; JPMorgan projects GLP-1 usage in the US could reach 30 million patients by 2030, with the cold chain packaging market expected to reach $71.6 billion by 2034.

With volume and distribution complexity growing in tandem, the ability to maintain consistent oversight becomes more difficult.

The key vulnerability this exposes is fragmentation – products no longer move through a single, controlled pathway; they pass through a series of independent environments, each with its own workflows.

And as those touchpoints multiply due to GLP-1 demand, so do the chances for inconsistencies in handling and gaps in accountability, making it harder to confidently assess product integrity.

HO: With GLP-1 therapies requiring a strict 2 to 8°C temperature range, how significant is the risk in the final “last mile” environment – in terms of both temperature control and other variables – and what does the industry still underestimate about what happens between pharmacy dispatch and patient receipt?

DP: The last mile introduces more variability and less oversight than earlier stages of the supply chain. Delivery timelines can change, packages may be exposed to fluctuating conditions, and products often sit unattended before receipt.

For therapies with narrow temperature tolerances, even short deviations carry consequences, particularly when they go unnoticed.

The financial scale of cold chain failures reflects how persistent this challenge is. The biopharmaceutical industry loses an estimated $35 billion annually due to breakdowns in temperature-controlled logistics, with many incidents occurring during transit and handling.

What the industry tends to underestimate is how last-mile risk factors converge. Delays, handling variability, and environmental exposure all overlap.

By the time a product reaches the patient, there is often no clear way to verify exactly what it experienced along the way, creating a black box with direct implications for product integrity and patient safety.

HO: As compounded and alternative GLP-1 products enter the market, how is the definition of cold chain accountability evolving beyond temperature control to include item-level authentication and traceability, such as Identiv’s BLE-enabled smart labels?

DP: That black box problem is precisely what is pushing accountability beyond temperature alone.

With more product types entering more distributed channels, knowing that a shipment stayed cold is no longer sufficient; you need to know that the product is genuine, traceable, and intact at the item-level.

Identiv’s BLE-enabled smart labels, with customizable configurations, support this by assigning each unit a unique digital identity to continuously capture and transmit critical data throughout its journey.

This creates a persistent item-level record that travels with the product, enabling verification of condition, provenance, and integrity at critical handoff points, including delivery.

As visibility becomes continuous, accountability evolves from being a compliance function into a dynamic data-driven capability.

The same item-level intelligence that enables traceability also powers predictive, automated, and responsive supply chains, where risks are identified earlier, interventions occur in real time, and the journey of sensitive therapies is continuously optimized from origin to patient.

HO: From Identiv’s perspective, what does true end-to-end visibility actually look like in a modern pharmaceutical supply chain, and how are your technologies helping close the gaps that exist today?

DP: True end-to-end visibility means the ability to follow each unit from origin to patient with a clear and continuous item-level record of its condition, integrity, and chain of custody, with data that can be accessed and acted on in real time without relying on retrospective reconstruction.

One of the primary challenges in achieving this is interoperability. Information is captured at multiple stages, but it often resides in disconnected systems that don’t communicate effectively.

Without consistent data exchange between platforms, it becomes difficult to assemble a complete and reliable view of a product’s movement.

Identiv addresses this by anchoring visibility at the source. Sensor-enabled labels capture temperature, humidity, movement, and handling in real time, and through collaborations with partners like Tag-N-Trac, that information can be integrated into cloud-based platforms designed to convert raw data into value for specific applications, such as cold-chain.

This makes it accessible across both transit and storage environments as events occur.

For GLP-1 therapies specifically, this enables teams to confirm product integrity in real time and respond before issues reach the patient.

HO: Looking ahead – and as continuous condition monitoring becomes increasingly pertinent – where is Identiv seeing the strongest demand for innovation? Temperature monitoring, authentication, or integrated solutions that combine both?

DP: Integrated solutions, without question. The conversations we’re having are no longer about solving for temperature or authentication in isolation; organizations want a complete picture at the item level. Where did this product originate? How did it move? Was it ever compromised?

Delivering that level of visibility becomes more complex as these therapies move through highly distributed supply chains.

With GLP-1 access expanding, products are passing through more partners and environments, increasing the number of handoffs and potential points of risk.

In response, we’re seeing growing interest in layered security models that combine overt and covert protections; overt features enabling fast and intuitive authentication as products change hands, and covert elements providing a deeper layer of security tied to each unit’s digital identity to guard against diversion, tampering, and counterfeiting throughout the journey.

Together, these approaches enable a coordinated end-to-end accountability model that connects first-, middle-, and last-mile distribution, built to support pharmaceutical access at unprecedented scale.

Sustainability is also emerging as an important driver of innovation. When temperature-sensitive products fall outside required conditions, they are discarded, and that waste accumulates quickly.

It’s been estimated that up to 50 percent of vaccines are wasted globally, with cold chain failures being a major contributing factor.

Real-time insight into product movement and handling enables earlier intervention, helping curb avoidable loss and supporting the move toward more efficient, circular supply chains.

The post Identiv : Strengthening Cold Chain Accountability for GLP-1 Therapies appeared first on Healthcare Outlook.

TECH-ENABLED SUCCESS

In the UK right now, nearly 650,000 people are currently out of work due to musculoskeletal (MSK) problems.

That’s 650,000 people who can’t do the jobs they want to do, support their families, or live the lives they planned. This isn’t just a healthcare crisis, but an economic one.

The NHS is tackling this with a preventative approach to care, starting with the rollout of the WorkWell scheme and, more recently, a tech-enabled programme designed to help patients manage their conditions remotely and get back to work sooner. 

The success of the programme demonstrates the importance of preventative care, with a 20 percent reduction in 18-week-plus community MSK waiting lists across the UK.

However, with an existing waiting list of 350,000, the NHS can’t address this crisis alone. To get Britain back to work, the government must also look to the private MSK sector – which already delivers a third of all physiotherapy – to accelerate efforts with tech-led interventions.

THE AGILITY ADVANTAGE

Technology plays a core role in scaling different types of MSK support across the country. Whether it’s connecting a patient to the right expert for treatment or facilitating remote care, digital solutions are needed to streamline patient pathways so a patient waiting three weeks can be seen in one.

When it comes to trialing and scaling solutions, the private sector has the advantage of being able to move faster than the public sector.

Private clinics can adopt new technology without the lengthy procurement cycles the NHS has to work through. That means they can integrate AI-driven triaging and automated workflows in weeks rather than years.

By working in tandem with the NHS, private providers can act as a fast-moving extension of national efforts to get people back to work.

Many clinics are adopting clinic management platforms to manage appointments, connect patients with the right specialists for their needs, and automate patient communications.

These features cut down on admin, free up clinicians’ time, and mean more patients can be seen – without increasing headcount costs. These are essential capabilities to help work through long NHS waiting lists.

PERSONALISED CARE

As well as helping practitioners to treat more patients, digital solutions can help MSK clinics provide more tailored care. Modern integrated platforms make specialist care more scalable – particularly with hybrid care models that combine remote and in-person treatment options.

For example, for a patient with limited mobility who would prefer to receive treatment at home, an integrated platform can give them greater control over their treatment plan with personalised exercise data and remote monitoring.

That means treatment that fits around the patient’s lifestyle, which contributes to faster progress and a return to work.

Beyond hybrid care models, digital tools also help clinics personalise care based on preferences such as language, gender and practitioner specialism, ensuring that patients receive the best care for their needs.

SCALING IMPACT

By adopting the right tools to manage admin, clinics can focus more on patient care and scale their operations to help more people.

A great example of this is a Belfast-based MSK clinic we work with that achieved a 100 percent year-on-year increase in new patient bookings by adopting automation features.

The clinic implemented TM3’s online booking portal, empowering patients to manage and change appointments themselves. That gave significant time back to clinics, which was reinvested into reaching new patients.

Paired with marketing integrations, it enabled the clinic to significantly grow its operations and see more patients.

This example is just one clinic. Scale that across every private MSK clinic in the country, and the numbers add up quickly.

GIVING MORE PEOPLE THE CHANCE TO GET BACK TO WORK

Solving the MSK crisis is essential to the UK’s general and economic health, and addressing workforce inactivity requires making use of every available resource.

Beyond NHS initiatives, the private sector has proven, practical technology that’s already helping MSK practitioners treat more patients faster and more effectively.

By empowering private clinics with technology, we can accelerate the successes we’ve already seen from government-led policies, help alleviate the strain on NHS waiting lists and make staying and returning to work a reality for hundreds of thousands of people.

The question for every private MSK clinic isn’t whether to adopt digital tools – it’s how quickly they can.

The post The Digital Backbone : Why private MSK clinics are the secret weapon in Britain’s ‘Back to Work’ strategy appeared first on Healthcare Outlook.